Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Target: Aldose Reductase
Epalrestat may affect or delay progression of the underlying disease process. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy [1]. Epalrestat significantly increased the amplitude of 3 cpm waves on EGG and improved the spectral analytical parameters of heart rate variability. These findings suggest that epalrestat is useful for the treatment of diabetic gastroparesis [2]. Epalrestat is a highly effective and safe agent for the treatment of diabetic neuropathy [3].
分子式
C15H13NO3S2
分子量
319.40
CAS号
82159-09-9
中文名称
依帕斯他;依帕司特;依帕司他;依帕司他
运输条件
Room temperature in continental US; may vary elsewhere.